David Cameron
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers
Papers in
- Cancer Research 196
- Breast Cancer Treatment Studies 194
- Oncology 167
- HER2/EGFR in Cancer Research 79
- Bone health and treatments 25
- Cancer survivorship and care 17
- Cancer Treatment and Pharmacology 14
- Co-authors
- J. Michael Dixon (16 shared papers)Martine J Piccart (28 shared papers)Charles E. Geyer (8 shared papers)R Stuart Anderson (8 shared papers)Luca Gianni (7 shared papers)Mario Campone (7 shared papers)Wilma J. L. Jack (14 shared papers)Ian H. Kunkler (12 shared papers)
- Journals
- Annals of Oncology (46 papers)European Journal of Cancer (45 papers)British Journal of Cancer (31 papers)The Lancet Oncology (29 papers)Journal of Clinical Oncology (28 papers)
- Partner nations
- United KingdomUnited StatesBelgium
In The Last Decade
David Cameron
416 papers receiving 46.3k citations
David Cameron's Hit Papers
Peers
Comparison fields: 5 of 166
- Cancer Research 17.5k
- Oncology 16.7k
- Pulmonary and Respiratory Medicine 6.9k
- Radiology, Nuclear Medicine and Imaging 1.9k
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by David Cameron
This map shows the geographic impact of David Cameron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cameron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cameron more than expected).
Fields of papers citing papers by David Cameron
This network shows the impact of papers produced by David Cameron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cameron. The network helps show where David Cameron may publish in the future.
Co-authors
The 25 scholars most cited alongside David Cameron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 433 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Hit paper breakdown → | 2005 | 4124 |
| 2 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Hit paper breakdown → | 2014 | 3695 |
| 3 | Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2006 | 2756 |
| 4 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Hit paper breakdown → | 2022 | 1933 |
| 5 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Hit paper breakdown → | 2016 | 1564 |
| 6 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Hit paper breakdown → | 2007 | 1246 |
| 7 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 992 |
| 8 | 2005 | 901 | |
| 9 | 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Hit paper breakdown → | 2010 | 864 |
| 10 | Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Hit paper breakdown → | 2017 | 859 |
| 11 | The benefits and harms of breast cancer screening: an independent review Hit paper breakdown → | 2013 | 838 |
| 12 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 806 |
| 13 | Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial Hit paper breakdown → | 2015 | 701 |
| 14 | 2010 | 689 | |
| 15 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Hit paper breakdown → | 2018 | 689 |
| 16 | 2008 | 631 | |
| 17 | 2005 | 629 | |
| 18 | Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Hit paper breakdown → | 2021 | 589 |
| 19 | Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 Hit paper breakdown → | 2021 | 583 |
| 20 | 2009 | 529 |
About David Cameron
David Cameron is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Public Health, Environmental and Occupational Health and Economics and Econometrics, having authored 433 papers that have together received 47.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (194 papers), HER2/EGFR in Cancer Research (79 papers), Advanced Breast Cancer Therapies (25 papers), Bone health and treatments (25 papers), Health Systems, Economic Evaluations, Quality of Life (19 papers), Cancer survivorship and care (17 papers), Cancer Treatment and Pharmacology (14 papers) and Estrogen and related hormone effects (14 papers). The work is most often cited by research in Cancer Research (17.5k citations), Oncology (16.7k citations), Pulmonary and Respiratory Medicine (6.9k citations), Radiology, Nuclear Medicine and Imaging (1.9k citations) and Pathology and Forensic Medicine (1.4k citations). David Cameron has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include J. Michael Dixon, Martine J Piccart, Charles E. Geyer, R Stuart Anderson, Luca Gianni, Mario Campone, Wilma J. L. Jack, Ian H. Kunkler, Cristina Oliva and Steven Stein. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, British Journal of Cancer, The Lancet Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.